<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230304057615N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-07-02</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of hydroalcoholic extract of oak in patients with gastroesophageal reflux disease (GERD)</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the efficacy of hydroalcoholic extract of Iranian oak (germ and seed coat) with proton pump inhibitor (PPI) treatment in improving the symptoms of patients with gastroesophageal reflux</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-09-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69427</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomized using block randomization method and using blocks of size 4. And the patients are divided into three groups of 30 people and blocked randomization is for the purpose of making sure that exactly equal number of participants are included in the intervention and control groups in consecutive but equal time intervals, Blinding description: Placebo ingredients will be filled in capsules of the same color and similar to the original drug, and then the drug, placebo and pantoprazole capsules (pantoprazole 40 mg capsule produced by Dorsa Daru Company) will be coded by the pharmacist and to prevent bias, all members of the treatment and research team will be unaware of the codes until the end of the research, and after the end of the treatment, the codes will be opened.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Gastroesophageal reflux.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group :First, the oaks of the Quercus Persica species will be collected from the forests of the Zagros mountains in Mal Agha village, Baghmelk city, Khuzestan province, and a sample of them will be handed over to the pharmacognosy group to determine the genus and species and obtain the herbarium code. After that, the oaks are peeled and screened for quality, and then they are dried in a suitable environment at a temperature of 30 to 40 degrees and away from sunlight. After that, the dried oak fruits are crushed and ground by a grinder machine and sent to Ibn Masowayeh plant processing plant to produce hydroalcoholic extract, and in standard and hygienic conditions, the desired extract is prepared by spray drying. and then its tannin and polyphenol percentage will be determined، For the formulation of 200 mg capsules, which will be done in the pharmaceutical growth center under the supervision of a pharmaceutical specialist, first the powder is mixed with the permitted auxiliary substances such as Avicel and magnesium stearate homogeneously and uniformly by the Eruka machine, and then in empty capsules of zero size and They will be filled with Iran gelatin brand by filling machine. Finally, the capsules are controlled by weight and ready for using.Capsules prepared from oak fruit extract are prepared in doses of 200 mg and patients take the medicine for 1 month in two times, morning and evening. Intervention 2: Control group 1: There are patients who will take pantoprazole 40 mg for 1 month , daily and before eating breakfast. Intervention 3: Control group2: There are patients who will take a placebo for 1 month in two times, morning and evening.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is there is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali Akbar Shayesteh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>24 metery street, East Sahely highway</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6193673166</zip>
        <telephone>+98 61 3222 2922</telephone>
        <email>shayeste-a@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Akbar Shayesteh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>24 metery street, East Sahely highway</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6193673166</zip>
        <telephone>+98 61 3222 2922</telephone>
        <email>shayeste-a@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients who are between 20 and 60 years old
Diagnosed with gastroesophageal reflux (GERD) based on clinical symptoms (having reflux at least twice a week), diagnostic endoscopy (esophagogastroduodenoscopy) and the Los Angeles classification (grades A to D)
Not taking PPI for at least 1 week before entering the study</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who are infected with H. pylori in the initial diagnostic examinations and before the intervention, based on stomach biopsy or stool test
Patients with coagulation disorders or GI bleeding
Patients who have a history of upper GI surgery or suffer from other digestive diseases such as irritable bowel syndrome, peptic ulcer, obstructive disease, etc
Patients with Zollinger-Ellison syndrome, primary motility disorders, Barrett's esophagus, esophageal stricture, and any severe disease with reflux and malignancy of the upper gastrointestinal tract, as well as pregnant or lactating women
Patients who take PPIs from 28 days before diagnostic endoscopy or H2 receptor antagonists from 14 days before diagnostic endoscopy
Patients who take NSAIDs or other drugs that may interfere with the interpretation of the study result. (diazepam, quinidine, Dilantin, warfarin, anticholinergics, prostaglandin analogs, or sucralfate)
Patients with chronic kidney, lung, and liver diseases and ...
Patients who have a history of sensitivity to pantoprazole or seasonal allergies or asthma
Patients who consume alcohol or drugs</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K21.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Gastro-esophageal reflux disease without esophagitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group :First, the oaks of the Quercus Persica species will be collected from the forests of the Zagros mountains in Mal Agha village, Baghmelk city, Khuzestan province, and a sample of them will be handed over to the pharmacognosy group to determine the genus and species and obtain the herbarium code. After that, the oaks are peeled and screened for quality, and then they are dried in a suitable environment at a temperature of 30 to 40 degrees and away from sunlight. After that, the dried oak fruits are crushed and ground by a grinder machine and sent to Ibn Masowayeh plant processing plant to produce hydroalcoholic extract, and in standard and hygienic conditions, the desired extract is prepared by spray drying. and then its tannin and polyphenol percentage will be determined، For the formulation of 200 mg capsules, which will be done in the pharmaceutical growth center under the supervision of a pharmaceutical specialist, first the powder is mixed with the permitted auxiliary substances such as Avicel and magnesium stearate homogeneously and uniformly by the Eruka machine, and then in empty capsules of zero size and They will be filled with Iran gelatin brand by filling machine. Finally, the capsules are controlled by weight and ready for using.Capsules prepared from oak fruit extract are prepared in doses of 200 mg and patients take the medicine for 1 month in two times, morning and evening.</i_keyword>
      <i_keyword>Control group 1: There are patients who will take pantoprazole 40 mg for 1 month , daily and before eating breakfast.</i_keyword>
      <i_keyword>Control group2: There are patients who will take a placebo for 1 month in two times, morning and evening.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Gastroesophageal reflux score in the health-related quality of life questionnaire. Timepoint: All patients are evaluated at the beginning of the study (before the intervention) and at the end of the first, second and fourth week. Method of measurement: Health-related quality of life questionnaire (related to GERD).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Gastroesophageal reflux score in frequency scale questionnaire for symptoms. Timepoint: All patients are evaluated at the beginning of the study (before the intervention) and at the end of the first, second and fourth week. Method of measurement: The frequency scale for the symptoms questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-03-12</approval_date>
        <contact_name>Ethics Committee of Ahvaz Jundi Shapur University of Medical Sciences</contact_name>
        <contact_address>Jundishapur University of Medical Sciences., Esfand St., Golestan Blvd., Ahvaz Ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
